Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Basic Net EPS Stands At $-0.3783

0

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) had an annual basic consolidated EPS of $-0.3995 for the period ended 2015-06-30. For the quarter ended 2015-06-30 which was on quarterly basis, the basic consolidated EPS reading was $-0.3995.

EPS from continuing operations

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) reported $-0.3995 as the basic EPS from continuing operations for the annual period ended 2015-06-30. Quarterly basic EPS from continuing operations stood at $-0.3995 for the three-month period ended 2015-06-30.

EPS contribution from parent

From its parent company, Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) received basic EPS of $-0.3995 for the annual period ended 2015-06-30. EPS contribution from the parent company was $-0.3995 which was on quarterly basis for the period ended 2015-06-30.

Basic net EPS

A basic net EPS of $-0.3783 was reported by Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) for the annual period ended 2015-06-30. For the three-month period ended 2015-06-30 which was on a quarterly basis, the company’s basic net EPS stood at $-0.3783.

Consolidated diluted EPS

For the period ended 2015-06-30, $-0.3995 was reported as the annual consolidated diluted EPS reading. Consolidated diluted EPS was $-0.3995 for the quarter ended 2015-06-30.

Basic diluted EPS

Diluted EPS reading from continuing operation was $-0.3995 which was on annual basis but for the period ended 2015-06-30. From continuing operations, Diluted EPS was $-0.3995 for the quarter ended 2015-06-30.

Net diluted EPS

Net diluted EPS reading was $-0.3783 for the annual period ended 2015-06-30 while the net diluted EPS for the quarterly period ended 2015-06-30 stood at $-0.3783.

Diluted EPS from parent

Diluted EPS of $-0.3995 was received by Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) from its parent company which was for the annual period ended 2015-06-30. For the quarter ended 2015-06-30, diluted EPS contribution from the parent was $-0.3995 on quarterly basis. For the annual period ended 2015-06-30, $-0.42 was posted by Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) as net basic EPS reading.

For the quarter ended 2015-06-30, basic net EPS of $-0.42 was reported. The period ended 2015-06-30 had annual average basic shares outstanding of 54.169. But it was 54.169 for the quarter ended 2015-06-30. 54.169 and 54.169 were the diluted shares outstanding for the fiscal year ended is 2015-06-30 respectively.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 18 times, 1 visits today)